Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Sells $1,340,510.00 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the transaction, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A. Sinclair Dunlop also recently made the following trade(s):

• On Friday, June 21st, A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS traded down $0.78 during mid-day trading on Tuesday, hitting $35.53. The company’s stock had a trading volume of 1,257,245 shares, compared to its average volume of 1,483,913. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of -10.49 and a beta of 0.88. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $33.49 and a fifty-two week high of $73.80. The stock has a fifty day moving average of $38.13 and a 200-day moving average of $44.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The company had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. During the same period last year, the business earned ($1.02) earnings per share. The business’s revenue was up 110.2% on a year-over-year basis. As a group, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on APLS. Wells Fargo & Company lowered their price target on Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating on the stock in a report on Thursday, May 23rd. Piper Sandler began coverage on shares of Apellis Pharmaceuticals in a report on Friday, May 31st. They issued a “neutral” rating and a $46.00 target price on the stock. Wedbush upped their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, August 9th. The Goldman Sachs Group lifted their price objective on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Needham & Company LLC restated a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a research note on Friday, August 9th. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $71.67.

Institutional Trading of Apellis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC bought a new position in shares of Apellis Pharmaceuticals in the first quarter valued at approximately $29,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Apellis Pharmaceuticals in the first quarter worth $89,000. nVerses Capital LLC grew its holdings in shares of Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after purchasing an additional 2,100 shares during the last quarter. CWM LLC increased its stake in shares of Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after buying an additional 3,113 shares in the last quarter. Finally, CWA Asset Management Group LLC bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at about $205,000. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).